PURPOSE: The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME. DESIGN: Prospective, randomized crossover clinical trial. METHODS:Twenty DME patients randomized todexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral-domain optical coherence tomography (SDOCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Crossover at week 16 provided changes in protein levels after each intervention in all 20 patients. RESULTS: After dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including 3 known PPFs: angiopoietin-2 (r = 0.40, P = .001), hepatocyte growth factor (HGF; r = 0.31, P = .02), and endocrine gland-VEGF (EG-VEGF, r = 0.43, P < .001). Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reduction after injection of a VEGF-neutralizing protein as well as dexamethasone implant, suggesting their modulation is likely secondary to changes in edema rather than causative. CONCLUSIONS: Correlation of edema reduction with reduction in the PPFs angiopoietin-2, HGF, and EG-VEGF provides potential insight into the multifactorial molecular mechanism by which dexamethasone implants reduce edema and suggest that additional study is needed to investigate the contributions of these 3 factors to chronic DME.
RCT Entities:
PURPOSE: The Diabetic Macular Edema Treated with Ozurdex (DMEO) Trial measured aqueous pro-permeability factors (PPFs) in diabetic macular edema (DME) patients before and after injection of dexamethasone implant or vascular endothelial growth factor (VEGF)-neutralizing protein and correlated changes in levels with changes in excess foveal thickness (EFT) to identify potential PPFs contributing to DME. DESIGN: Prospective, randomized crossover clinical trial. METHODS: Twenty DMEpatients randomized to dexamethasone implant or VEGF-neutralizing protein had aqueous taps and spectral-domain optical coherence tomography (SDOCT) at baseline and every 4 weeks for 28 weeks. Aqueous levels of 55 vasoactive proteins were measured with protein array. Crossover at week 16 provided changes in protein levels after each intervention in all 20 patients. RESULTS: After dexamethasone implant there was significant correlation between changes in levels of 13 vasoactive proteins with changes in EFT, including 3 known PPFs: angiopoietin-2 (r = 0.40, P = .001), hepatocyte growth factor (HGF; r = 0.31, P = .02), and endocrine gland-VEGF (EG-VEGF, r = 0.43, P < .001). Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reduction after injection of a VEGF-neutralizing protein as well as dexamethasone implant, suggesting their modulation is likely secondary to changes in edema rather than causative. CONCLUSIONS: Correlation of edema reduction with reduction in the PPFs angiopoietin-2, HGF, and EG-VEGF provides potential insight into the multifactorial molecular mechanism by which dexamethasone implants reduce edema and suggest that additional study is needed to investigate the contributions of these 3 factors to chronic DME.
Authors: Allen C Clermont; Mark Cahill; Haytham Salti; Susan L Rook; Christian Rask-Madsen; Lucy Goddard; Jun S Wong; Dahlia Bursell; Sven E Bursell; Lloyd Paul Aiello Journal: Invest Ophthalmol Vis Sci Date: 2006-06 Impact factor: 4.799
Authors: Peter A Campochiaro; Gulnar Hafiz; Tahreem A Mir; Adrienne W Scott; Raafay Sophie; Syed M Shah; Howard S Ying; Lili Lu; Connie Chen; J Peter Campbell; Saleema Kherani; Ingrid Zimmer-Galler; Adam Wenick; Ian Han; Yannis Paulus; Akrit Sodhi; Guohua Wang; Jiang Qian Journal: Am J Ophthalmol Date: 2015-04-20 Impact factor: 5.258
Authors: Jikui Shen; Maike Frye; Bonnie L Lee; Jessica L Reinardy; Joseph M McClung; Kun Ding; Masashi Kojima; Huiming Xia; Christopher Seidel; Raquel Lima e Silva; Aling Dong; Sean F Hackett; Jiangxia Wang; Brian W Howard; Dietmar Vestweber; Christopher D Kontos; Kevin G Peters; Peter A Campochiaro Journal: J Clin Invest Date: 2014-09-02 Impact factor: 14.808
Authors: S F Hackett; H Ozaki; R W Strauss; K Wahlin; C Suri; P Maisonpierre; G Yancopoulos; P A Campochiaro Journal: J Cell Physiol Date: 2000-09 Impact factor: 6.384
Authors: Quan Dong Nguyen; Syed Mahmood Shah; Jeffery S Heier; Diana V Do; Jennifer Lim; David Boyer; Prema Abraham; Peter A Campochiaro Journal: Ophthalmology Date: 2009-08-22 Impact factor: 12.079
Authors: Raquel Lima E Silva; Yogita Kanan; Adam C Mirando; Jayoung Kim; Ron B Shmueli; Valeria E Lorenc; Seth D Fortmann; Jason Sciamanna; Niranjan B Pandey; Jordan J Green; Aleksander S Popel; Peter A Campochiaro Journal: Sci Transl Med Date: 2017-01-18 Impact factor: 17.956
Authors: Sruthi Arepalli; Charles C Wykoff; Joseph R Abraham; Leina Lunasco; Hannah Yu; Ming Hu; Sunil K Srivastava; Jamie L Reese; David Brown; Justis P Ehlers Journal: Eye (Lond) Date: 2022-10-11 Impact factor: 4.456
Authors: Joseph R Abraham; Charles C Wykoff; Sruthi Arepalli; Leina Lunasco; Hannah J Yu; Alison Martin; Christopher Mugnaini; Ming Hu; Jamie Reese; Sunil K Srivastava; David M Brown; Justis P Ehlers Journal: Br J Ophthalmol Date: 2021-06-07 Impact factor: 5.908